(NASDAQ: SLS) Sellas Life Sciences Group's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 25.97%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.35%.
Sellas Life Sciences Group's earnings in 2025 is -$26,259,000.On average, 4 Wall Street analysts forecast SLS's earnings for 2025 to be -$28,293,430, with the lowest SLS earnings forecast at -$29,104,220, and the highest SLS earnings forecast at -$27,640,586. On average, 4 Wall Street analysts forecast SLS's earnings for 2026 to be -$36,317,097, with the lowest SLS earnings forecast at -$39,518,140, and the highest SLS earnings forecast at -$33,168,703. 
In 2027, SLS is forecast to generate -$34,569,159 in earnings, with the lowest earnings forecast at -$36,117,032 and the highest earnings forecast at -$33,168,703.